ACT-EARLY is testing the hypothesis that treating asymptomatic carriers of a pathogenic TTR variant with the drug acoramidis could delay amyloidosis from developing.
The Philips Azurion interventional imaging system was recently updated with new ultralow dose technology that is said to reduce X-ray exposure by up to 50% during coronary procedures.
Researchers tracked data from nearly 400 women with complex CAD who underwent treatment with Shockwave Medical's intravascular lithotripsy technology prior to PCI.
Finerenone, sold under the brand name Kerendia, is already approved by the FDA for reducing heart and kidney risks in patients with chronic kidney disease (CKD) and type 2 diabetes. Bayer plans on presenting the new data in full at ESC Congress 2024 in London.
Cardiac researcher Masoud Pezeshkian, MBBS, became one of the world's most widely known cardiac surgeons in the world when he officially became Iran's president.
The organization is teaming up with CereMark Pharma to conduct research on improving outcomes in soldiers and athletes with neurodegenerative conditions.
Most EP clinical study data are from men, Anne Kroman, DO, explained in an interview. This is a significant problem, she said, because heart rhythm issues look quite different in women.
A conference on neurology is described by reporters as "shambolic," offering only bare bones presentations and accommodations. And the number of these events may be on the rise.
